Briacell Therapeutics Corp (BCTX)

$11.31 -0.97 (-7.90%)
Market Cap 23.13M
Revenue (ttm) 0.00
Net Income (ttm) -26.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 97,200
Avg Vol 68,608
Day's Range N/A - N/A
Shares Out 1.88M
Stochastic %K 54%
Beta 1.38
Analysts Strong Buy
Price Target $40.00

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 921 1810
Fax: 604 921 1898
Address:
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada
DunkenInvest
DunkenInvest Dec. 11 at 9:34 AM
$BCTX I didnt see any bad news yesterday? Why is this going down again? Is people really disappointed with the results, or did they just expect miracles? People are really way to negative in the stock market 🫤
1 · Reply
Rohtan
Rohtan Dec. 11 at 3:33 AM
$BCTX only good thing about this stock is that there is no offering out yet for a while.
0 · Reply
superguild
superguild Dec. 11 at 1:46 AM
$BCTX i guess the pumpers are off the clock now
0 · Reply
superguild
superguild Dec. 11 at 12:18 AM
$BCTX we are still reasonable on the Stocktwits Bullish sentiment. Wonder where we are on the Bullshit sentiment?
0 · Reply
JohnHarden
JohnHarden Dec. 10 at 6:07 PM
$BCTX BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout https://finance.yahoo.com/news/briacell-phase-3-patient-enrollment-123000551.html
0 · Reply
option_zone_06
option_zone_06 Dec. 10 at 5:52 PM
$BCTX microcap biotech, low attention and thin float, wait for volume ignition for confirm
0 · Reply
Richapeslayer_pounce
Richapeslayer_pounce Dec. 10 at 5:45 PM
$BCTX Sold multiple lots in small amounts earlier , didn't get the peak but still happy.
2 · Reply
AceInHole
AceInHole Dec. 10 at 5:44 PM
$BCTX share price performance playing out exactly as expected, following a great PR. Classic train wreck, garbage POS stock.
0 · Reply
Arcides
Arcides Dec. 10 at 5:18 PM
$BCTX disgrace price action on supposed to be good news. -24% from premarket high.
0 · Reply
JohnHarden
JohnHarden Dec. 10 at 5:12 PM
Small Cap Stock Alert: $BCTX Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025 – “Bria-IMT regimen to address major unmet needs in the treatment of metastatic breast cancer”
0 · Reply
Latest News on BCTX
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Dec 10, 2025, 7:30 AM EST - 1 day ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Dec 9, 2025, 7:30 AM EST - 2 days ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Dec 2, 2025, 7:30 AM EST - 9 days ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 16 days ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 20, 2025, 7:30 AM EST - 21 days ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 18, 2025, 7:30 AM EST - 23 days ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 7, 2025, 7:30 AM EST - 4 weeks ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Nov 4, 2025, 7:30 AM EST - 5 weeks ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Oct 22, 2025, 7:30 AM EDT - 7 weeks ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:50 AM EDT - 7 weeks ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 21, 2025, 7:30 AM EDT - 7 weeks ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 20, 2025, 7:30 AM EDT - 7 weeks ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 2 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Oct 3, 2025, 7:30 AM EDT - 2 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 26, 2025, 7:30 AM EDT - 3 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 25, 2025, 7:30 AM EDT - 3 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 21, 2025, 12:00 PM EDT - 3 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Aug 13, 2025, 7:30 AM EDT - 4 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 31, 2025, 7:30 AM EDT - 4 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 30, 2025, 7:30 AM EDT - 4 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 29, 2025, 7:30 AM EDT - 4 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 25, 2025, 7:30 AM EDT - 4 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 16, 2025, 4:05 PM EDT - 5 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 5 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 15, 2025, 7:30 AM EDT - 5 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 5 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 10, 2025, 7:30 AM EDT - 5 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 9, 2025, 7:30 AM EDT - 5 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 8, 2025, 7:30 AM EDT - 5 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jul 2, 2025, 7:30 AM EDT - 5 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 24, 2025, 7:30 AM EDT - 6 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 4, 2025, 7:30 AM EDT - 6 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

Jun 2, 2025, 7:30 AM EDT - 6 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 27, 2025, 7:30 AM EDT - 7 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 23, 2025, 7:30 AM EDT - 7 months ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

BriaCell CEO Letter to Shareholders

May 20, 2025, 7:30 AM EDT - 7 months ago

BriaCell CEO Letter to Shareholders

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Apr 30, 2025, 7:30 AM EDT - 8 months ago

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Apr 28, 2025, 4:05 PM EDT - 8 months ago

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Apr 28, 2025, 7:30 AM EDT - 8 months ago

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Apr 24, 2025, 8:00 PM EDT - 8 months ago

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

Apr 24, 2025, 10:11 AM EDT - 8 months ago

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

Apr 24, 2025, 7:30 AM EDT - 8 months ago

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

Apr 23, 2025, 7:30 AM EDT - 8 months ago

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

Apr 22, 2025, 7:30 AM EDT - 8 months ago

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Apr 16, 2025, 7:30 AM EDT - 8 months ago

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

Mar 26, 2025, 8:00 AM EDT - 9 months ago

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer

Mar 20, 2025, 8:00 AM EDT - 9 months ago

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Feb 5, 2025, 6:15 PM EST - 11 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Therapeutics Announces Closing of Public Offering

Feb 5, 2025, 4:05 PM EST - 11 months ago

BriaCell Therapeutics Announces Closing of Public Offering

BriaCell Therapeutics Announces Pricing of Public Offering

Feb 3, 2025, 7:59 PM EST - 11 months ago

BriaCell Therapeutics Announces Pricing of Public Offering

DunkenInvest
DunkenInvest Dec. 11 at 9:34 AM
$BCTX I didnt see any bad news yesterday? Why is this going down again? Is people really disappointed with the results, or did they just expect miracles? People are really way to negative in the stock market 🫤
1 · Reply
Rohtan
Rohtan Dec. 11 at 3:33 AM
$BCTX only good thing about this stock is that there is no offering out yet for a while.
0 · Reply
superguild
superguild Dec. 11 at 1:46 AM
$BCTX i guess the pumpers are off the clock now
0 · Reply
superguild
superguild Dec. 11 at 12:18 AM
$BCTX we are still reasonable on the Stocktwits Bullish sentiment. Wonder where we are on the Bullshit sentiment?
0 · Reply
JohnHarden
JohnHarden Dec. 10 at 6:07 PM
$BCTX BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout https://finance.yahoo.com/news/briacell-phase-3-patient-enrollment-123000551.html
0 · Reply
option_zone_06
option_zone_06 Dec. 10 at 5:52 PM
$BCTX microcap biotech, low attention and thin float, wait for volume ignition for confirm
0 · Reply
Richapeslayer_pounce
Richapeslayer_pounce Dec. 10 at 5:45 PM
$BCTX Sold multiple lots in small amounts earlier , didn't get the peak but still happy.
2 · Reply
AceInHole
AceInHole Dec. 10 at 5:44 PM
$BCTX share price performance playing out exactly as expected, following a great PR. Classic train wreck, garbage POS stock.
0 · Reply
Arcides
Arcides Dec. 10 at 5:18 PM
$BCTX disgrace price action on supposed to be good news. -24% from premarket high.
0 · Reply
JohnHarden
JohnHarden Dec. 10 at 5:12 PM
Small Cap Stock Alert: $BCTX Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025 – “Bria-IMT regimen to address major unmet needs in the treatment of metastatic breast cancer”
0 · Reply
JediGreen
JediGreen Dec. 10 at 4:49 PM
$BCTX short sellers out. Went doubt if it’s above 13 after 2 PM after we know what the federal reserve is doing.
1 · Reply
SWTex
SWTex Dec. 10 at 4:45 PM
$BCTX offering in…..
0 · Reply
JediGreen
JediGreen Dec. 10 at 4:29 PM
$BCTX 2pm EST We will know.
1 · Reply
JediGreen
JediGreen Dec. 10 at 4:26 PM
$BCTX Whole market waiting on the Federal Reserve. 🥱
0 · Reply
JohnHarden
JohnHarden Dec. 10 at 2:30 PM
Cancer Stock News: Is $BCTX Close to a breakthrough in the fight against breast cancer? Company “Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025” Read the full press release here: https://globenewswire.com/news-release/2025/12/10/3203069/0/en/BriaCell-Presents-Outstanding-Phase-2-Survival-Promising-Phase-3-Clinical-Data-at-SABCS-2025.html
0 · Reply
Ichigodoran
Ichigodoran Dec. 10 at 1:34 PM
Cancer Stock News: Is $BCTX Close to a breakthrough in the fight against breast cancer? Company “Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025” Read the full press release here: https://globenewswire.com/news-release/2025/12/10/3203069/0/en/BriaCell-Presents-Outstanding-Phase-2-Survival-Promising-Phase-3-Clinical-Data-at-SABCS-2025.html
0 · Reply
JJBurch
JJBurch Dec. 10 at 1:29 PM
$BCTX they have a cure for cancer no big deal. Haha. Wow. Price target $150 $MIGI undervalued crypto play POST RS should go 1000% runner. Yeah. I mean it. Eyes on it folks $TSLA $NVDA $MSTR
0 · Reply
Richapeslayer_pounce
Richapeslayer_pounce Dec. 10 at 1:06 PM
$BCTX Sold at $13.36 brought at $10.08 around a 32% profit in under 2 weeks,onto the next one , good luck today for anyone holding.
1 · Reply
JohnTrack
JohnTrack Dec. 10 at 12:48 PM
$BCTX results released https://www.rapidticker.com/news/bctx-briacell-presents-outstanding-phase-2-b210f0
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Dec. 10 at 12:39 PM
$BCTX BriaCell Shares Survival And Biomarker Results For Breast Cancer Therapy At Major San Antonio Conference
0 · Reply
SmallCapVoice
SmallCapVoice Dec. 10 at 12:35 PM
BriaCell ( $BCTX ) shows strong Phase 2 survival and promising Phase 3 biomarker data at SABCS 2025: outstanding long term survival and no toxicity related discontinuations. Read the full press release here: https://www.globenewswire.com/news-release/2025/12/10/3203069/0/en/BriaCell-Presents-Outstanding-Phase-2-Survival-Promising-Phase-3-Clinical-Data-at-SABCS-2025.html
0 · Reply
MrTicker
MrTicker Dec. 10 at 12:34 PM
$BCTX BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025 GLOBENEWSWIRE 6:30 AM ET 12/10/2025
0 · Reply